Entrada Therapeutics annual operating margin
2023
2024
2025
Entrada Therapeutics's operating margin was −621.13% for fiscal 2025.
View full Entrada Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −621.13% | −643.44 pp |
| 2024 | 2024-12-31 | 22.30% | +24.75 pp |
| 2023 | 2023-12-31 | −2.45% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −5,007.02% | −2604.50 pp |
| Q1 2026 | 2026-03-31 | −4,834.63% | −4728.64 pp |
| Q4 2025 | 2025-12-31 | −3,249.27% | −3233.58 pp |
| Q3 2025 | 2025-09-30 | −2,915.18% | −2804.51 pp |
| Q2 2025 | 2025-06-30 | −2,402.51% | −2458.93 pp |
| Q1 2025 | 2025-03-31 | −105.99% | −141.70 pp |
| Q4 2024 | 2024-12-31 | −15.69% | −27.41 pp |
| Q3 2024 | 2024-09-30 | −110.67% | −142.71 pp |
| Q2 2024 | 2024-06-30 | 56.42% | +146.12 pp |
| Q1 2024 | 2024-03-31 | 35.71% | +58.59 pp |
| Q4 2023 | 2023-12-31 | 11.72% | — |
| Q3 2023 | 2023-09-30 | 32.04% | — |
| Q2 2023 | 2023-06-30 | −89.70% | — |
| Q1 2023 | 2023-03-31 | −22.88% | — |
Across the available reported history, Entrada Therapeutics's operating margin decreased from 22.30% to −621.13%, a change of −643.44 percentage points. The latest reported quarter, Q2 2026, shows −5,007.02%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Entrada Therapeutics filings at SEC.gov ↗